5 Lessons Doctors Can Take From FDA's Big Stem-Cell Win

Law360, New York (February 7, 2014, 7:22 PM EST) -- The D.C. Circuit on Tuesday delivered a loud wake-up call to stem cell clinics when it endorsed strong oversight by the U.S. Food and Drug Administration, but doctors can take comfort in a number of exceptions and strategies that could limit the ruling's reach.

At issue were treatments by Colorado-based Regenerative Sciences LLC that involve extracting cells and letting them multiply in a laboratory setting — a process the appeals court said crossed the line into drug manufacturing, triggering FDA scrutiny. That's a costly setback for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.